KR20240128110A - Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 - Google Patents

Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 Download PDF

Info

Publication number
KR20240128110A
KR20240128110A KR1020247026710A KR20247026710A KR20240128110A KR 20240128110 A KR20240128110 A KR 20240128110A KR 1020247026710 A KR1020247026710 A KR 1020247026710A KR 20247026710 A KR20247026710 A KR 20247026710A KR 20240128110 A KR20240128110 A KR 20240128110A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
antagonist
dose
skin
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247026710A
Other languages
English (en)
Korean (ko)
Inventor
닐 그레이엄
마리우스 아르델레아누
앨런 라딘
제니퍼 디. 해밀턴
아리엘 테퍼
Original Assignee
리제너론 파아마슈티컬스, 인크.
사노피 바이오테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51663113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20240128110(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파아마슈티컬스, 인크., 사노피 바이오테크놀로지 filed Critical 리제너론 파아마슈티컬스, 인크.
Publication of KR20240128110A publication Critical patent/KR20240128110A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020247026710A 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 Pending KR20240128110A (ko)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201461946237P 2014-02-28 2014-02-28
US61/946,237 2014-02-28
US201461952245P 2014-03-13 2014-03-13
US61/952,245 2014-03-13
US201461986371P 2014-04-30 2014-04-30
US61/986,371 2014-04-30
EP14306476 2014-09-24
EP14306476.4 2014-09-24
US201562100128P 2015-01-06 2015-01-06
US62/100,128 2015-01-06
PCT/US2015/017834 WO2015130975A1 (en) 2014-02-28 2015-02-26 Methods for treating skin infection by administering an il-4r antagonist
KR1020227016206A KR102695088B1 (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227016206A Division KR102695088B1 (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법

Publications (1)

Publication Number Publication Date
KR20240128110A true KR20240128110A (ko) 2024-08-23

Family

ID=51663113

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247026710A Pending KR20240128110A (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
KR1020167023138A Ceased KR20160120735A (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
KR1020227016206A Active KR102695088B1 (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020167023138A Ceased KR20160120735A (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
KR1020227016206A Active KR102695088B1 (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법

Country Status (13)

Country Link
US (3) US10370449B2 (enExample)
EP (2) EP4353254A3 (enExample)
JP (1) JP6526037B2 (enExample)
KR (3) KR20240128110A (enExample)
CN (1) CN106062000B (enExample)
AU (2) AU2015222951B2 (enExample)
CA (1) CA2939506C (enExample)
ES (1) ES2973858T3 (enExample)
MX (1) MX376691B (enExample)
PL (1) PL3110848T3 (enExample)
PT (1) PT3110848T (enExample)
RU (1) RU2704999C2 (enExample)
WO (1) WO2015130975A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
RU2690675C2 (ru) 2012-08-21 2019-06-05 Санофи Байотекнолоджи Способы лечения или предотвращения астмы посредством введения антагониста il-4r
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
MX2017006286A (es) 2014-11-14 2018-01-23 Sanofi Biotechnology Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
EP4442323A3 (en) 2016-09-01 2025-01-01 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
KR20250111396A (ko) 2017-09-05 2025-07-22 아지트라 인코포레이티드 재조합 미생물을 사용하여 염증성 피부 질환을 치료하기 위한 방법 및 조성물
KR20250044796A (ko) 2017-10-30 2025-04-01 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
CN111494626B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
EP3935085A1 (en) * 2019-03-06 2022-01-12 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
PH12021552123A1 (en) 2019-03-21 2022-08-22 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
JP7592064B2 (ja) 2019-07-16 2024-11-29 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
BR112022011098A2 (pt) 2019-12-09 2022-09-20 Sanofi Biotechnology Métodos para tratamento de distúrbios relacionados a il-4/il-13 digitalmente identificados
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
EP0668774A1 (en) 1991-05-03 1995-08-30 Seragen, Inc. Interleukin receptor targeted molecules for treatment of inflammatory arthritis
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
ES2259478T3 (es) 1998-09-18 2006-10-01 Dynavax Technologies Corporation Metodos para tratar trastornos asociados con la ige y composiciones para este uso.
ES2382891T3 (es) 2000-05-26 2012-06-14 Immunex Corporation Uso de anticuerpos IL-4R y sus composiciones
US20020002132A1 (en) * 2000-05-26 2002-01-03 Pluenneke John D. Use of interleukin-4 antagonists and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP1304115B1 (en) 2000-07-26 2007-09-12 Hououdou Co. Ltd. Antipruritic compositions and compositions promoting wound healing
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
CA2446108A1 (en) 2001-05-11 2002-11-21 Novartis Ag Compositions for use in treating ige-associated disorders
CA2447795A1 (en) 2001-05-23 2002-11-28 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
DK1461300T3 (da) 2001-11-30 2011-10-24 Biogen Idec Inc Antistoffer mod kemotaktiske monocytproteiner
PT1527100E (pt) 2002-03-29 2009-08-25 Schering Corp Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
AU2004209637A1 (en) 2003-02-01 2004-08-19 Tanox, Inc. A method for generating high affinity antibodies
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
CA2543982C (en) 2003-11-07 2013-01-08 Immunex Corporation Antibodies that bind interleukin-4 receptor
CA2550933A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
ATE395358T1 (de) 2004-02-27 2008-05-15 Regeneron Pharma Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
WO2006083390A2 (en) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101522716B (zh) 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
NZ580553A (en) 2007-03-22 2012-05-25 Genentech Inc Apoptotic anti- ige antibodies binding the membrane-bound ige
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
WO2010065557A2 (en) 2008-12-01 2010-06-10 Cincinnati Children's Hospital Medical Center Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
EP2414520A2 (en) 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
CN107320722A (zh) 2009-09-07 2017-11-07 Dbv技术公司 治疗嗜酸细胞性食管炎的方法
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
EP2585075B8 (en) 2010-06-24 2021-09-22 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
JP5918246B2 (ja) 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
WO2012094643A2 (en) 2011-01-06 2012-07-12 Children's Hospital Medical Center Esophageal cytokine expression profiles in eosinophilic esophagitis
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
CA2840086A1 (en) 2011-06-21 2012-12-27 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
WO2013051928A1 (en) 2011-10-06 2013-04-11 N.V. Nutricia Treatment of eosinophilic esophagitis
JP2015500326A (ja) 2011-12-16 2015-01-05 アトピックス テラピューティクス リミテッド 好酸球性食道炎の治療のためのｃｒｔｈ２拮抗薬およびプロトンポンプ阻害薬の組み合わせ
BR112014018471A2 (pt) 2012-01-31 2017-07-04 Genentech Inc anticorpos anti-ige m1' e métodos para o seu uso
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
RU2690675C2 (ru) 2012-08-21 2019-06-05 Санофи Байотекнолоджи Способы лечения или предотвращения астмы посредством введения антагониста il-4r
ES2981062T3 (es) * 2012-09-07 2024-10-07 Regeneron Pharma Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
WO2014059178A1 (en) 2012-10-10 2014-04-17 Rhode Island Hospital Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis
JP2016507523A (ja) 2013-02-05 2016-03-10 エンクマフ アーゲー ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
EP3613432B1 (en) 2013-06-21 2025-08-06 Sanofi Biotechnology Methods for treating nasal polyposis by administering an il-4r antagonist
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
MX2017006286A (es) 2014-11-14 2018-01-23 Sanofi Biotechnology Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
ES2983475T3 (es) 2016-02-19 2024-10-23 Regeneron Pharma Métodos para mejorar la eficacia de una vacuna mediante la administración de un antagonista de IL-4R
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP4442323A3 (en) 2016-09-01 2025-01-01 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
EP4345110A3 (en) 2016-09-22 2024-06-12 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
KR20250044796A (ko) 2017-10-30 2025-04-01 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
PH12021552123A1 (en) 2019-03-21 2022-08-22 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
BR112022011098A2 (pt) 2019-12-09 2022-09-20 Sanofi Biotechnology Métodos para tratamento de distúrbios relacionados a il-4/il-13 digitalmente identificados
IL298257A (en) 2020-05-22 2023-01-01 Regeneron Pharma Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
US20220220211A1 (en) 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist

Also Published As

Publication number Publication date
US11603408B2 (en) 2023-03-14
EP3110848A1 (en) 2017-01-04
MX2016011132A (es) 2016-12-08
CA2939506C (en) 2022-08-23
KR20220070544A (ko) 2022-05-31
RU2704999C2 (ru) 2019-11-01
PL3110848T3 (pl) 2024-06-10
US20230357416A1 (en) 2023-11-09
MX376691B (es) 2025-03-07
EP4353254A2 (en) 2024-04-17
AU2020204350A1 (en) 2020-07-16
US10370449B2 (en) 2019-08-06
WO2015130975A1 (en) 2015-09-03
EP3110848B1 (en) 2024-02-14
PT3110848T (pt) 2024-03-05
ES2973858T3 (es) 2024-06-24
US20190367622A1 (en) 2019-12-05
AU2015222951B2 (en) 2020-06-11
CA2939506A1 (en) 2015-09-03
CN106062000B (zh) 2021-05-28
KR102695088B1 (ko) 2024-08-16
RU2016130056A3 (enExample) 2018-11-12
AU2020204350B2 (en) 2023-03-23
EP4353254A3 (en) 2024-07-03
JP2017512193A (ja) 2017-05-18
AU2015222951A1 (en) 2016-08-25
CN106062000A (zh) 2016-10-26
US20150246973A1 (en) 2015-09-03
KR20160120735A (ko) 2016-10-18
RU2016130056A (ru) 2018-04-02
JP6526037B2 (ja) 2019-06-05

Similar Documents

Publication Publication Date Title
US20230357416A1 (en) Methods for treating skin infection by administering an il-4r antagonist
US20240082353A1 (en) Methods for preventing or treating allergy by administering an il-4r antagonist
JP2025172841A (ja) Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
JP2021147383A (ja) アトピー性皮膚炎及び関連障害を処置するための方法
KR20250096792A (ko) Il-4r 길항제를 투여하여 손 및 발 피부염을 치료하기 위한 방법
TW202317184A (zh) 用於治療異位性皮膚炎和相關障礙之方法
HK40102414A (en) Methods for treating skin infection by administering an il-4r antagonist
RU2801204C2 (ru) Способ лечения атопического дерматита посредством введения ингибитора ил-4r
HK1228934B (en) Methods for treating skin infection by administering an il-4r antagonist
HK1228934A1 (en) Methods for treating skin infection by administering an il-4r antagonist
AU2017321682B2 (en) Methods for preventing or treating allergy by administering an IL-4R antagonist
HK40111341A (en) Methods for preventing or treating allergy by administering an il-4r antagonist
RU2777328C2 (ru) Способы предупреждения или лечения аллергии посредством введения антагониста il-4r
HK40009524B (en) Methods for preventing or treating allergy by administering an il-4r antagonist
HK40009524A (en) Methods for preventing or treating allergy by administering an il-4r antagonist

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701